Predicting Local and Distant Recurrence in T1 Colorectal Cancer

Launched by CITY OF HOPE MEDICAL CENTER · Mar 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict whether patients with early-stage colorectal cancer (specifically, T1 colorectal cancer) will experience a recurrence of their cancer after treatment. Recurrence means that the cancer comes back after it has been removed, and understanding who is at higher risk can help doctors provide better follow-up care. The trial aims to identify reliable markers that can indicate which patients are more likely to remain cancer-free after their initial treatment.

To be eligible for this study, participants must be adults aged 65 to 74 who have been diagnosed with stage I T1 colorectal cancer and have undergone a standard treatment to remove the cancer. They also need to be cancer-free at the time they join the study. Participants will be closely monitored throughout the study to assess their health and any signs of recurrence. This research is important because it could lead to improved care and support for patients who have undergone treatment for colorectal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Stage I, pT1 colorectal cancer (TNM classification, 8th edition).
• • Received standard diagnostic, staging, and stage-specific curative-intent resection (endoscopic or surgical, as per local guidelines).
• • Confirmed cancer-free survivorship at the time of study inclusion.
• Exclusion Criteria:
• • Lack of informed consent.
• • Induction of neoadjuvant systemic therapy before colorectal cancer resection.
• • Synchronous colorectal and non-colorectal cancer diagnosed at or before surgery.